Sodium-glucose cotransporter 2 inhibitors (SGLT2i), initially born as anti-diabetic drugs, have shown many beneficial effects on the cardiovascular system, in particular against heart failure (HF). HF is a complex and multifaceted disease that requires a comprehensive approach. It should not be considered as a simplistic cardiac disease, but a systemic disease that leads to multisystemic organ failure and death. Exploiting their pleiotropic effects, SGLT2i are a very valid tool for HF treatment. Beyond the indication to reduce HF hospitalization and death risk, in patients with diabetes mellitus at high cardiovascular risk or with established cardiovascular event, SGLT2i administration reported beneficial effects regarding the wide spectrum of HF manifestations and stages, independently by diabetes mellitus presence. Recent evidence focuses on HF rehospitalization, cardiac and all-cause death reduction, as well as symptoms and quality of life improvement, in patients with chronic HF or with a recent HF decompensation episode. Given the recent finding about the SGLT2i usefulness in HF patients, further studies are needed to define the best administration timing to maximize the SGLT2i-derived beneficial effects.

钠-葡萄糖协同转运蛋白 2 抑制剂 (SGLT2i) 最初是作为抗糖尿病药物诞生的，已显示出对心血管系统的许多有益作用，尤其是抗心力衰竭 (HF)。心力衰竭是一种复杂的多方面疾病，需要综合治疗。它不应被视为一种简单的心脏病，而是一种导致多系统器官衰竭和死亡的全身性疾病。利用它们的多效性，SGLT2i 是一种非常有效的 HF 治疗工具。除了降低 HF 住院和死亡风险的适应症外，在心血管风险高或已确定心血管事件的糖尿病患者中，SGLT2i 给药报告了对广泛的 HF 表现和阶段的有益影响，独立于糖尿病的存在。最近的证据集中在慢性心衰或近期心衰失代偿发作患者的心衰再住院、心脏和全因死亡减少以及症状和生活质量改善上。鉴于最近关于 SGLT2i 在 HF 患者中的有用性的发现，需要进一步研究来确定最佳给药时间以最大化 SGLT2i 衍生的有益效果。